Market Segmentation Global Glucagon-Like Peptide-1 Agonists Market Size, Share & Industry Analysis, By Product Type (Short-Acting GLP-1 Agonists, Long-Acting GLP-1 Agonists), By Route of Administration (Injectable, Oral), By Application (Type 2 Diabetes, Obesity Management, Cardiovascular Disease Management), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Analysis and Forecast 20262035 Global Glucagon-Like Peptide-1 Agonists Market Size & Statistics The Market size of global glucagon-like peptide-1 agonists was estimated to be worth USD 46.18 Billion in 2025
Food and Drug Administration (FDA) in 2017 for managing blood sugar, Ozempic and other semaglutide medications help prevent complications of diabetes by improving insulin release and lowering glucose levels (U.S
doi: 10.1016/j.arr.2023.101855, 30
doi: 10.1056/NEJM199205143262003 16 NauckMA
